Skip to main content
. 2022 Dec 7;10:1059597. doi: 10.3389/fcell.2022.1059597

TABLE 2.

Characteristic comparison of early death among bone metastatic breast cancer patients in the training group.

Characteristic Overall Early death p
No Yes
n 14,582 12,061 2,521
Age [mean (SD)] 61.65 (14.04) 60.42 (13.83) 67.51 (13.53) <0.001
Sex (%) 0.279
 Female 14,403 (98.8) 11,907 (98.7) 2,496 (99.0)
 Male 179 (1.2) 154 (1.3) 25 (1.0)
Race (%) 0.237
 American Indian/Alaska Native 92 (0.6) 79 (0.7) 13 (0.5)
 Asian or Pacific Islander 1,104 (7.6) 925 (7.7) 179 (7.1)
 Black 2,130 (14.6) 1741 (14.4) 389 (15.4)
 White 11,201 (76.8) 9,266 (76.8) 1,935 (76.8)
 Unknown 55 (0.4) 50 (0.4) 5 (0.2)
Marital status (%) <0.001
 Married (which includes common law) 6,370 (43.7) 5,517 (45.7) 853 (33.8)
 Separated, divorced, or widowed 4,157 (28.5) 3,243 (26.9) 914 (36.3)
 Single (never married) 3,199 (21.9) 2,594 (21.5) 605 (24.0)
 Others 856 (5.9) 707 (5.9) 149 (5.9)
Geographic areas (%) 0.013
 Metropolitan counties 12,927 (88.7) 10,734 (89.0) 2,193 (87.0)
 Nonmetropolitan counties 1,635 (11.2) 1,312 (10.9) 323 (12.8)
 Unknown 20 (0.1) 15 (0.1) 5 (0.2)
Laterality (%) <0.001
 Bilateral, single primary 90 (0.6) 65 (0.5) 25 (1.0)
 Left—origin of primary 6,970 (47.8) 5,828 (48.3) 1,142 (45.3)
 Only one side—side unspecified 48 (0.3) 39 (0.3) 9 (0.4)
 Paired site, but no information concerning laterality 697 (4.8) 509 (4.2) 188 (7.5)
 Right—origin of primary 6,777 (46.5) 5,620 (46.6) 1,157 (45.9)
Brain metastasis (%) <0.001
 No 13,031 (89.4) 10,986 (91.1) 2,045 (81.1)
 Unknown 504 (3.5) 367 (3.0) 137 (5.4)
 Yes 1,047 (7.2) 708 (5.9) 339 (13.4)
Liver metastasis (%) <0.001
 No 10,843 (74.4) 9,421 (78.1) 1,422 (56.4)
 Unknown 375 (2.6) 284 (2.4) 91 (3.6)
 Yes 3,364 (23.1) 2,356 (19.5) 1,008 (40.0)
Lung metastasis (%) <0.001
 No 10,279 (70.5) 8,872 (73.6) 1,407 (55.8)
 Unknown 506 (3.5) 376 (3.1) 130 (5.2)
 Yes 3,797 (26.0) 2,813 (23.3) 984 (39.0)
T stage (%) <0.001
 T0 313 (2.1) 257 (2.1) 56 (2.2)
 T1 1,655 (11.3) 1,454 (12.1) 201 (8.0)
 T2 3,795 (26.0) 3,315 (27.5) 480 (19.0)
 T3 2,004 (13.7) 1,739 (14.4) 265 (10.5)
 T4 4,037 (27.7) 3,254 (27.0) 783 (31.1)
 TX 2,778 (19.1) 2,042 (16.9) 736 (29.2)
N stage (%) <0.001
 N0 3,468 (23.8) 2,824 (23.4) 644 (25.5)
 N1 6,255 (42.9) 5,295 (43.9) 960 (38.1)
 N2 1,297 (8.9) 1,140 (9.5) 157 (6.2)
 N3 1,730 (11.9) 1,528 (12.7) 202 (8.0)
 NX 1,832 (12.6) 1,274 (10.6) 558 (22.1)
Histologic type (%) <0.001
 Adenomas and adenocarcinomas 973 (6.7) 734 (6.1) 239 (9.5)
 Ductal and lobular neoplasms 12,205 (83.7) 10,489 (87.0) 1,716 (68.1)
 Epithelial neoplasms, NOS 967 (6.6) 629 (5.2) 338 (13.4)
 Squamous cell neoplasms 14 (0.1) 9 (0.1) 5 (0.2)
 Unspecified neoplasms 352 (2.4) 147 (1.2) 205 (8.1)
 Others 71 (0.5) 53 (0.4) 18 (0.7)
Grade (%) <0.001
 Grade I 767 (5.3) 702 (5.8) 65 (2.6)
 Grade II 3,738 (25.6) 3,265 (27.1) 473 (18.8)
 Grade III 3,357 (23.0) 2,844 (23.6) 513 (20.3)
 Grade IV 51 (0.3) 45 (0.4) 6 (0.2)
 Unknown 6,669 (45.7) 5,205 (43.2) 1,464 (58.1)
ER status (%) <0.001
 Borderline/unknown 1,338 (9.2) 716 (5.9) 622 (24.7)
 Negative 2,172 (14.9) 1,647 (13.7) 525 (20.8)
 Positive 11,072 (75.9) 9,698 (80.4) 1,374 (54.5)
PR status (%) <0.001
 Borderline/unknown 1,497 (10.3) 850 (7.0) 647 (25.7)
 Negative 4,167 (28.6) 3,328 (27.6) 839 (33.3)
 Positive 8,918 (61.2) 7,883 (65.4) 1,035 (41.1)
HER2 (%) <0.001
 Borderline/unknown 2001 (13.7) 1,249 (10.4) 752 (29.8)
 Negative 9,784 (67.1) 8,420 (69.8) 1,364 (54.1)
 Positive 2,797 (19.2) 2,392 (19.8) 405 (16.1)
Cancer-directed surgery (%) <0.001
 No 11,077 (76.0) 8,722 (72.3) 2,355 (93.4)
 Unknown 244 (1.7) 225 (1.9) 19 (0.8)
 Yes 3,261 (22.4) 3,114 (25.8) 147 (5.8)
Radiation (%) <0.001
 No/unknown 9,664 (66.3) 7,681 (63.7) 1983 (78.7)
 Yes 4,918 (33.7) 4,380 (36.3) 538 (21.3)
Chemotherapy (%) <0.001
 No/unknown 6,852 (47.0) 4,930 (40.9) 1922 (76.2)
 Yes 7,730 (53.0) 7,131 (59.1) 599 (23.8)

SD, standard deviation; T, tumor; N, nodes; NOS, not otherwise specified; ER, estrogen receptor; PR, progesterone receptor; HER2, human epidermal growth factor receptor-2.